Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17925776 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | Final Rejection | University of Florida Research Foundation, Inc. |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | Final Rejection | New York University |
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18009537 | CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | Non-Final OA | Sanofi |
| 18265156 | Octahydroisoquinolinyl Derivatives | Non-Final OA | UCB Biopharma SRL |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy